Donor germ-line variants associate with outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromes

Paul L Auer; Manzur Farazi; Tao Zhang; Jing Dong; Yung-Tsi Bolon; Stephen R Spellman; Wael Saber

doi:10.1002/ajh.27243

Donor germ-line variants associate with outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromes

Am J Hematol. 2024 Apr;99(4):770-773. doi: 10.1002/ajh.27243. Epub 2024 Feb 9.

Authors

Paul L Auer^{1

2}, Manzur Farazi¹, Tao Zhang³, Jing Dong^{2

4

5}, Yung-Tsi Bolon³, Stephen R Spellman³, Wael Saber⁶

Affiliations

¹ Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
² Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, USA.
³ CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program®/Be The Match®, Minneapolis, Minnesota, USA.
⁴ Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
⁵ Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
⁶ Division of Hematology and Oncology, Department of Medicine, CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

PMID: 38339773
PMCID: PMC10947828 (available on 2025-04-01)
DOI: 10.1002/ajh.27243

Abstract

Overall survival probability for MDS patients who underwent allo-HCT and were matched to donors that are wild-type (red) and heterozygous (blue) for the rs111224634 SNP.

Publication types

Letter

MeSH terms

Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Humans
Myelodysplastic Syndromes* / genetics
Myelodysplastic Syndromes* / therapy
Retrospective Studies
Tissue Donors
Transplantation Conditioning

Abstract

Publication types

MeSH terms

Grants and funding